Loss of 10q26.1-q26.3 in association with 7q34-q36.3 gain or 17q24.3-q25.3 gain predict poor outcome in pediatric medulloblastoma

Cancer Letters

Volumn 308, Issue 2, 2011, Pages 215-224

  Pezzolo, Annalisa ^a   Coco, Simona ^b   Raso, Alessandro ^a   Parodi, Federica ^a   Pistorio, Angela ^a   Valdora, Francesca ^c   Capra, Valeria ^a   Zollo, Massimo ^d   Aschero, Simona ^e   Basso, Eleonora ^e   Cama, Armando ^a   Nozza, Paolo ^a   Gambini, Claudio ^a   Cinalli, Giuseppe ^f   Garrè, Maria Luisa ^a   Iolascon, Achille ^d   Pistoia, Vito ^a   Tonini, Gian Paolo ^b  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

^f SANTOBONO PAUSILIPON CHILDREN S HOSPITAL   (Italy)

Author keywords

CGH; Chromosomal imbalances; FISH; LOH; Medulloblastoma

Indexed keywords

ARTICLE; CANCER SURVIVAL; CANCER TISSUE; CHILD; CHROMOSOME 10Q; CHROMOSOME 17Q; CHROMOSOME 7Q; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; FEMALE; GENETIC ANALYSIS; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEDULLOBLASTOMA; PEDIATRICS; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CHROMOSOMES, HUMAN, PAIR 10; CHROMOSOMES, HUMAN, PAIR 17; CHROMOSOMES, HUMAN, PAIR 7; COMPARATIVE GENOMIC HYBRIDIZATION; HUMANS; INFANT; LOSS OF HETEROZYGOSITY; MEDULLOBLASTOMA; MULTIVARIATE ANALYSIS; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79959556385     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.05.006     Document Type: Article

References (48)

1. F. Giangaspero, C. Eberhart, H. Haapasalo, T. Pietsch, O.D. Wiestler, D.W. Ellison, Medulloblastoma, in: D.N. Louis, H. Ohgaki, D. Wiestler, W.K. Cavenee (Eds.), WHO Classification of Tumours of the Central Nervous System, IARC Press, Lyon, 2007, pp. 132-140.
2. J. Kuhl, F. Doz, R.E. Taylor, Embryonic tumors, in: D.A. Walke, G. Perilongo, J.A.G. Punt, R.E. Taylor (Eds.), Brain, and Spinal Tumors of Childhood, Arnold, London, 2004, pp. 314-30.
3. Harisiadis L., Chang C.H. Medulloblastoma in children: a correlation between staging and results of treatment. Int. J. Radiat. Oncol. Biol.Phys. 1977, 2:833-841.
4. Laurent J.P., Chang C.H., Cohen M.E. A classification system for primitive neuroectodermal tumors (medulloblastoma) of the posterior fossa. Cancer 1985, 56:1807-1809.
5. Bailey P., Cushing H. Medulloblastoma cerebelli: a common type of mid-cerebellar glioma of childhood. Arch. Neurol. Psychiatry 1925, 14:192-224.
6. Gandola L., Massimino M., Cefalo G., Solero C., Spreafico F., Pecori E., Riva D., Collini P., Pignoli E., Giangaspero F., Luksch R., Berretta S., Poggi G., Biassoni V., Ferrari A., Pollo B., Favre C., Sardi I., Terenziani M., Fossati-Bellani F. Hyperfractionated accelerated radiotherapy in the Milan strategy for metastatic medulloblastoma. J. Clin. Oncol. 2009, 27:566-571.
7. Gilbertson R.J. Medulloblastoma: signalling a change in treatment. Lancet Oncol. 2004, 5:209-218.
8. Gottardo N.G., Gajjar A. Current therapy for medulloblastoma. Curr. Treat. Options Neurol. 2006, 8(4):319-334.
9. Rutkowski S., von Bueren A., von Hoff K., Hartmann W., Shalaby T., Deinlein F., Warmuth-Metz M., Soerensen N., Emser A., Bode U., Mittler U., Urban C., Benesch M., Kortmann R.D., Schlegel P.G., Kuehl J., Pietsch T., Grotzer M. Prognostic relevance of clinical and biological risk factors in childhood medulloblastoma: results of patients treated in the prospective multicenter trial HIT'91. Clin. Cancer Res. 2007, 13(9):2651-2657.
10. Packer R.J., Rood B.R., MacDonald T.J. Medulloblastoma: present concepts of stratification into risk groups. Pediatr. Neurosurg. 2003, 39(2):60-67.
11. Ellison D. Classifying the medulloblastoma: insights from morphology and molecular genetics. Neuropathol. Appl. Neurobiol. 2002, 28:257-282.
12. Garrè M.L., Cama A., Bagnasco F., Morana G., Giangaspero F., Brisigotti M., Gambini C., Forni M., Rossi A., Haupt R., Nozza P., Barra S., Piatelli G., Viglizzo G., Capra V., Bruno W., Pastorino L., Massimino M., Tumolo M., Fidani P., Dallorso S., Schumacher R.F., Milanaccio C., Pietsch T. Medulloblastoma variants: age-dependent occurrence and relation to Gorlin syndrome: a new clinical perspective. Clin. Cancer Res. 2009, 15:2463-2471.
13. Giangaspero F., Rigobello L., Badiali M., Loda M., Andreini L., Basso G., Zorzi F., Montaldi A. Large-cell medulloblastomas. A distinct variant with highly aggressive behavior. Am. J. Surg. Pathol. 1992, 16:687-693.
14. Ellison D.W., Onilude O.E., Lindsey J.C., Lusher M.E., Weston C.L., Taylor R.E., Pearson A.D., Clifford S.C. United Kingdom children's cancer study group brain tumour committee: Beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom children's cancer study group brain tumour committee. J. Clin. Oncol. 2005, 23:7951-7957.
15. Bayani J., Zielenska M., Marrano P., Kwan Ng Y., Taylor M.D., Jay V., Rutka J.T., Squire J.A. Molecular cytogenetic analysis of medulloblastomas and supratentorial primitive neuroectodermal tumors by using conventional banding, comparative genomic hybridization, and spectral karyotyping. J. Neurosurg. 2000, 93:437-448.
16. Michiels E.M., Weiss M.M., Hoovers J.M., Baak J.P., Voûte P.A., Baas F., Hermsen M.A. Genetic alterations in childhood medulloblastoma analyzed by comparative genomic hybridization. J. Pediatr. Hematol. Oncol. 2002, 24:205-210.
17. Hui A.B., Takano H., Lo K.W., Kuo W.L., Lam C.N., Tong C.Y., Chang Q., Gray J.W., Ng H.K. Identification of a novel homozygous deletion region at 6q23.1 in medulloblastomas using high resolution array comparative genomic hybridization analysis. Clin. Cancer Res. 2005, 11:4707-4716.
18. Pan E., Pellarin M., Holmes E., Smirnov I., Misra A., Eberhart C.G., Burger P.C., Biegel J.A., Feuerstein B.G. Isochromosome 17q is a negative prognostic factor in poor-risk childhood medulloblastoma patients. Clin. Cancer. Res. 2005, 11:4733-4740.
19. McCabe M.G., Ichimura K., Liu L., Plant K., Bäcklund L.M., Pearson D.M., Collins V.P. High resolution array-based comparative genomic hybridization of medulloblastomas and supratentorial primitive neuroectodermal tumors. J. Neuropathol. Exp. Neurol. 2006, 65:549-561.
20. Rossi M.R., Conroy J., McQuaid D., Nowak N.J., Rutka J.T., Cowell J.K. Array CGH analysis of pediatric medulloblastomas. Genes Chrom. Cancer 2006, 45:290-303.
21. Biegel J.A., Rorke L.B., Packer R.J., Sutton L.N., Schut L., Bonner K., Emanuel B.S. Isochromosome 17q in primitive neuroectodermal tumors of the central nervous system. Genes Chrom. Cancer 1989, 1:139-147.
22. Lamont J.M., McManamy C.S., Pearson A.D., Clifford S.C., Ellison D.W. Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients. Clin. Cancer Res. 2004, 10:5482-5493.
23. Lo K.C., Rossi M.R., Eberhart C.G., Cowell J.K. Genome wide copy number abnormalities in pediatric medulloblastomas as assessed by array comparative genome hybridization. Brain Pathol. 2007, 17:282-296.
24. Pfister S., Remke M., Benner A., Mendrzyk F., Toedt G., Felsberg J., Wittmann A., Devens F., Gerber N.U., Joos S., Kulozik A., Reifenberger G., Rutkowski S., Wiestler O.D., Radlwimmer B., Scheurlen W., Lichter P., Korshunov A. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN Loci. J. Clin. Oncol. 2009, 27:1627-1636.
25. Aldosari N., Bigner S.H., Burger P.C., Becker L., Kepner J.L., Friedman H.S., McLendon R.E. MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group. Arch. Pathol. Lab. Med. 2002, 126:540-544.
26. Tong C.Y., Hui A.B., Yin X.L., Pang J.C., Zhu X.L., Poon W.S., Ng H.K. Detection of oncogene amplifications in medulloblastomas by comparative genomic hybridization and array-based comparative genomic hybridization. J. Neurosurg. 2004, 100:187-193.
27. Emadian S.M., McDonald J.D., Gerken S.C., Fults D. Correlation of chromosome 17p loss with clinical outcome in medulloblastoma. Clin. Cancer Res. 1996, 2:1559-1564.
28. Ferretti E., De Smaele E., Di Marcotullio L., Screpanti I., Gulino A. Hedgehog checkpoints in medulloblastoma: the chromosome 17p deletion paradigm. Trends Mol. Med. 2005, 11:537-545.
29. Cho Y.J., Tsherniak A., Tamayo P., Santagata S., Ligon A., Greulich H., Berhoukim R., Amani V., Goumnerova L., Eberhart C.G., Lau C.C., Olson J.M., Gilbertson R.J., Gajjar A., Delattre O., Kool M., Ligon K., Meyerson M., Mesirov J.P., Pomeroy S.L. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J. Clin. Oncol. 2010, 6. (Epub ahead of print).
30. Kool M., Koster J., Bunt J., Hasselt N.E., Lakeman A., van Sluis P., Troost D., Meeteren N.S., Caron H.N., Cloos J., Mrsić A., Ylstra B., Grajkowska W., Hartmann W., Pietsch T., Ellison D., Clifford S.C., Versteeg R. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One 2008, 3:e3088.
31. Korshunov A., Remke M., Werft W., Benner A., Ryzhova M., Witt H., Sturm D., Wittmann A., Schöttler A., Felsberg J., Reifenberger G., Rutkowski S., Scheurlen W., Kulozik A.E., von Deimling A., Lichter P., Pfister S.M. Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification. J. Clin. Oncol. 2010, 28:3054-3060.
32. Coco S., Valdora F., Bonassi S., Scaruffi P., Stigliani S., Oberthuer A., Berthold F., Andolfo I., Servidei T., Riccardi R., Basso E., Iolascon A., Tonini G.P. Chromosome 9q and 16q loss identified by genome-wide pooled-analysis are associated with tumor aggressiveness in patients with classic medulloblastoma. OMICS 2011, 15:273-280.
33. B. Gokart, J. Schmidtke, J.J. Cassiman, S. Aymé, Data Storage and DNA Banking for Biomedical Research: Informed Consent, Confidentiality, Quality Issue, Ownership, Return of Benefits, A Professional Perspective, EUROGAPP PROJECT 1999-2000.
34. Pezzolo A., Capra V., Raso A., Morandi F., Parodi F., Gambini C., Nozza P., Giangaspero F., Cama A., Pistoia V., Garrè M.L. Identification of novel chromosomal abnormalities and prognostic cytogenetics markers in intracranial pediatric ependymoma. Cancer Lett. 2008, 261:235-243.
35. Pezzolo A., Parodi F., Corrias M.V., Cinti R., Gambini C., Pistoia V. Tumor origin of endothelial cells in human neuroblastoma. J. Clin. Oncol. 2007, 25:376-383.
36. Kallioniemi A., Kallioniemi O.P., Sudar D., Rutovitz D., Gray J.W., Waldman F., Pinkel D. Comparative genomic hybridization for molecular cytogenetics analysis of solid tumors. Science 1992, 258:818-821.
37. Lucito R., Healy J., Alexander J., Reiner A., Esposito D., Chi M., Rodgers L., Brady A., Sebat J., Troge J., West J.A., Rostan S., Nguyen K.C., Powers S., Ye K.Q., Olshen A., Venkatraman E., Norton L., Wigler M. Representational oligonucleotide microarray analysis: a high-resolution method to detect genome copy number variation. Genome Res. 2003, 13:2291-2305.
38. Kuga D., Mizoguchi M., Guan Y., Hata N., Yoshimoto K., Shono T., Suzuki S.O., Kukita Y., Tahira T., Nagata S., Sasaki T., Hayashi K. Prevalence of copy-number neutral LOH in glioblastomas revealed by genomewide analysis of laser-microdissected tissues. Neuro Oncol. 2008, 10:995-1003.
39. Yin X.L., Pang J.C., Liu Y.H., Chong E.Y., Cheng Y., Poon W.S., Ng H.K. Analysis of loss of heterozygosity on chromosomes 10q, 11, and 16 in medulloblastomas. J. Neurosurg. 2001, 94:799-805.
40. Mollenhauer J., Herbertz S., Holmskov U., Tolnay M., Krebs I., Merlo A., Schroder H.D., Maier D., Breitling F., Wiemann S., Grone H.J., Poustka A. DMBT1 encodes a protein involved in the immune defense and in epithelial differentiation and is highly unstable in cancer. Cancer Res. 2000, 60:1704-1710.
41. Mollenhauer J., Wiemann S., Scheurlen W., Korn B., Hayashi Y., Wilgenbus K.K., von Deimling A., Poustka A. DMBT1, a new member of the SRCR super-family, on chromosome 10q25.3-26.1 is deleted in malignant brain tumors. Nat. Genet. 1997, 17:32-39.
42. Somerville R.P., Shoshan Y., Eng C., Barnett G., Miller D., Cowell J.K. Molecular analysis of two putative tumour suppressor genes, PTEN and DMBT, which have been implicated in glioblastoma multiforme disease progression. Oncogene 1998, 17:1755-1757.
43. Wu W., Kemp B.L., Proctor M.L., Gazdar A.F., Minna J.D., Hong W.K., Mao L. Expression of DMBT1, a candidate tumor suppressor gene, is frequently lost in lung cancer. Cancer Res. 1999, 59:1846-1851.
44. Mori M., Shiraishi T., Tanaka S., Yamagata M., Mafune K., Tanaka Y., Ueo H., Barnard G.F., Sugimachi K. Lack of DMBT1 expression in oesophageal, gastric and colon cancers. Br. J. Cancer 1999, 79:211-213.
45. Pang J.C., Dong Z., Zhang R., Liu Y., Zhou L.F., Chan B.W., Poon W.S., Ng H.K. Mutation analysis of DMBT1 in glioblastoma, medulloblastoma and oligodendroglial tumors. Int. J. Cancer 2003, 105:76-81.
46. Ramírez de Molina A., Gallego-Ortega D., Sarmentero J., Bañez-Coronel M., Martín-Cantalejo Y., Lacal J.C. Choline kinase is a novel oncogene that potentiates RhoA-induced carcinogenesis. Cancer Res. 2005, 65:5647-5653.
47. Berger R., Fiegl H., Goebel G., Obexer P., Ausserlechner M., Doppler W., Hauser-Kronberger C., Reitsamer R., Egle D., Reimer D., Müller-Holzner E., Jones A., Widschwendter M. Toll-like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumors. Cancer Sci. 2010, 101:1059-1066.
48. Ren D., Minami Y., Nishita M. Critical role of Wnt5a-Ror2 signaling in motility and invasiveness of carcinoma cells following Snail-mediated epithelial-mesenchymal transition. Genes Cells 2011, 16:304-315.